Petrelintide

2 papers4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs

Human trial2

Outcomes

Body weight

downin humans2

2 studies

Petrelintide decreases body weight in humans (up to 10.7% vs 1.7% for placebo).
“Petrelintide led to mean reductions in body weight from baseline to Week 42 of up to 10.7% vs 1.7% for placebo (efficacy estimand; p<0.001).”
Human trialobesity or overweight with complications42 weeksn = 485
Petrelintide, a Human Amylin Analog for the Treatment of Obesity: Efficacy and Safety from the Phase 2 Trial, ZUPREME 1
ADA Scientific Sessions 2026 abstract5 Jun 2026
Petrelintide decreases body weight in humans (-4.8%, -8.6%, -8.3% vs -1.7% placebo).
“mean BW decreased by 4.8, 8.6 and 8.3% and WC by 5.0, 7.2 and 7.6 cm with the three petrelintide doses versus 1.7% (BW) and 1.9 cm (WC) for pooled placebo”
Human trial16 weeks
Effects of the Novel Long-Acting Amylin Analogue Petrelintide on Body Weight and Waist Circumference by Sex in a Phase 1 Trial
ADA Scientific Sessions 2025 abstract13 Jun 2025

Cardiovascular risk factors

upin humans1

1 study

Petrelintide improves cardiovascular risk factors in humans.
“Petrelintide was associated with meaningful improvements in key cardiovascular risk factors (hs-CRP, lipids, BP and waist circumference).”
Human trialobesity or overweight with complications42 weeksn = 485
Petrelintide, a Human Amylin Analog for the Treatment of Obesity: Efficacy and Safety from the Phase 2 Trial, ZUPREME 1
ADA Scientific Sessions 2026 abstract5 Jun 2026